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Abstract
Patient-derived tumor xenograft (PDTX) approach is nowadays considered a reliable pre-
clinical model to study in vivo cancer biology and therapeutic response. NOD scid and Il2rg-
deficient mice represent the “gold standard” host for the generation of PDTXs. Compared to
other immunocompromised murine lines, these mice offers several advantages including
higher engraftment rate, longer lifespan and improved morphological and molecular preser-
vation of patient-derived neoplasms. Here we describe a spectrum of previously uncharac-
terized post-transplant disorders affecting 14/116 (12%) NOD.Cg- Prkdcscid Il2rgtm1Sug/
JicTac (NOG) mice subcutaneously engrafted with patient-derived metastatic melanomas.
Affected mice exhibited extensive scaling/crusting dermatitis (13/14) associated with emaci-
ation (13/14) and poor/unsuccessful tumor engraftment (14/14). In this context, the following
pathological conditions have been recognized and characterized in details: (i) immunoin-
flammatory disorders with features of graft versus host disease (14/14); (ii) reactive lym-
phoid infiltrates effacing xenografted tumors (8/14); (iii) post-transplant B cell lymphomas
associated with Epstein-Barr virus reactivation (2/14). We demonstrate that all these entities
are driven by co-transplanted human immune cells populating patient-derived tumor sam-
ples. Since the exploding interest in the utilization of NOD scid and Il2rg-deficient mice for
the establishment of PDTX platforms, it is of uppermost importance to raise the awareness
of the limitations associated with this model. The disorders here described adversely impact
tumor engraftment rate and animal lifespan, potentially representing a major confounding
factor in the context of efficacy and personalized therapy studies. The occurrence of these
conditions in the NOGmodel reflects the ability of this mouse line to promote efficient en-
graftment of human immune cells. Co-transplanted human lymphoid cells have indeed the
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potential to colonize the recipient mouse initiating the post-transplant conditions here re-
ported. On the other hand, the evidence of an immune response of human origin against
the xenotransplanted melanoma opens intriguing perspectives for the establishment of suit-
able preclinical models of anti-melanoma immunotherapy.
Introduction
Patient-derived tumor xenograft (PDTX) approach is nowadays considered one of the most ac-
curate preclinical tools to study in vivo biology and therapeutic response of individual human
cancers [1,2]. A variety of PDTX models have been successfully established for preclinical/clin-
ical drug testing and biomarker identification in diverse human neoplasms including ovarian,
pancreatic, breast, skin and prostate cancers [2–7]. In this context, PDTX approach has been
shown to be biologically stable and accurately reflect the original patient tumor with regards to
expression profile, mutational spectrum and molecular signaling [4,5,8].
NOD scid mice with Il2rg deficiency [i. e. NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG mice
from The Jackson Laboratory) and NOD.Cg- Prkdcscid Il2rgtm1Sug/JicTac (NOG mice from Ta-
conic)] combine several genetic defects that primarily affect the immune system leading to a se-
vere impairment of both innate and adaptive immune response. NOD background is
characterized by a loss of function mutation in the C5 hemolytic complement gene and by a
unique MHC haplotype, which leads to impaired natural killer cell function and defects in anti-
gen-presenting activity. Homozygosity for the Prkdcscid mutation results in defective somatic
recombination at T cell receptor and immunoglobulin chains loci with consequent defective
development and maturation of T and B cell clones. The targeted mutation in the γ chain of
the IL-2 receptor leads to deficiencies in cytokine signaling and failure of clonal lymphocyte ex-
pansion [9–14].
Thanks to their profound immunodeficiency status, NSG and NOGmice represent the
“gold standard” host for xenotransplantation experiments including patient-derived tumor bi-
opsies. When compared to other immunocompromised murine lines, NSG and NOGmice ex-
hibit higher PDTX engraftment rate and improved preservation of original patient tumor in
terms of morphological features, tumor microenvironment and cellular heterogeneity [15–18].
Additional advantages of NSG and NOGmice over the other immunodeficient strains include
lower predisposition for the development of spontaneous tumors, longer lifespan and no T
and/or B cell “leakiness” documented so far [10,12,14].
Recent studies demonstrated the relevance of NOD scid mice with deficient Il2rg for the def-
inition of phenotypic heterogeneity, tumorigenicity and metastatic potential of patient-derived
melanomas in vivo [19–21]. Based on these promising results, the PDTX platform at University
Hospitals Leuven established a NOGmodel-based pipeline with the aim to provide interested
research groups with an invaluable preclinical tool to dissect the molecular landscapes that
drive melanoma development and progression and test novel targeted therapeutic strategies on
a large scale [2].
In this work, we characterize at clinical, pathological and molecular level the development
of a spectrum of previously uncharacterized post-transplant disorders affecting NOGmice en-
grafted with patient-derived metastatic melanomas. All these pathological conditions are driv-
en by co-transplanted human immune cells populating patient-derived tumor samples and
represent important limitations in the context of PDTX models as they adversely impact on
tumor engraftment rate and animal lifespan.
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Materials and Methods
Collection, examination and xenotransplantation of human tumor
biopsies
All the original melanoma biopsies included in the PDTX platform were received freshly from
the operation theatre and promptly processed as follow. One representative part was fixed in
10% neutral buffered formalin, and used for routine histopathological diagnosis. A second por-
tion immediately adjacent to the one selected for histopathology was used for xenotransplanta-
tion. To ensure that the tumor was adequately represented in this latter specimen,
histopathology was also performed on thin tissue slices obtained from the sample destined for
xenotransplantation (S1 Table). The remainder of the biopsy was snap frozen in liquid nitro-
gen-cooled isopentane and stored at -80°C. The portion of the biopsy selected for xenotrans-
plantation was transported in RPMI 1640 medium supplemented with penicillin (100 U/ml),
streptomycin (100 μg/ml), fungizone (1 μg/ml) and gentamicin (50 μg/ml) all from Life Tech-
nologies. The sample was then briefly rinsed PBS (also supplemented with penicillin, strepto-
mycin and fungizone at the same concentrations) and minced into minute tissue fragments
which were eventually inoculated subcutaneously in the interscapular fat pad of 6-week-old
NOG females. Procedures for collection, preparation and transplantation of tumor biopsies
were performed under sterile conditions.
Regarding the 6 metastatic melanomas (i.e. 4 cases of nodal metastasis, 1 case of in transit
metastasis and 1 case of hepatic metastasis) considered in this study, serial sections obtained
from formalin-fixed and paraffin-embedded samples were immunostained for melanocytic
markers Melan-A, tyrosinase and HMB45, as well as for the B-cell/plasma cell markers and the
immunoglobulin light chains using commercially available antibodies on a Dako or Ventana
automated staining platform (see S2 Table for more details about the procedures). In addition,
ISH for Epstein-Barr virus-encoded RNA (EBER1-2) and immunostaining for Human Herpes-
virus 8 (HHV-8) was performed on the original biopsy material used for xenotransplantation
(see S2 Table for more details about the procedures). Procedures involving human samples
were approved by the UZ Leuven/KU Leuven Medical Ethical Committee (Commissie Med-
ische Ethiek, approval number ML8713/S54185). All participants have given written informed
consent before inclusion in the study. All signed informed consents have been collected and ar-
chived. Protocols for the generation, collection and recording of written informed consents
have been formally approved by the supervising ethic committee/IRB.
Animals and Husbandry
The 14 affected mice considered in this study were adult NOG females. All mice were part of
the first transplant (F1) generation in the context of 6 different patient-derived metastatic mel-
anoma experiments. S1 Table provides an overview of the entire patient-derived melanoma
platform and highlights the distribution of the affected F1 animals in the context of the differ-
ent PDTX experiments. In the F1 generation, material from metastatic melanoma biopsies is
transplanted subcutaneously in the interscapular region of 6-week-old animals as described in
the previous section. During the entire course of the experiment, mice were multiply housed (4
mice) in individual ventilated cages (Tecnilab, Blue Line IVCs) containing BK8/15 Lignocel
wood bedding (J. Rettenmaier & Söhne GmbH) in a semi-SPF A2 facility at the Laboratory An-
imal Center KU Leuven. Food (standard rodent diet Ssniff R/M-H) and UV-filtered drinking
water were provided ad libitum. Animal rooms were maintained at 22°C ± 2°C with a 45% and
70% relative humidity range, 50 air changes per hour and twelve-hour light/dark cycles. Mice
were included in a health monitoring program developed in accordance with Federation of
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European Laboratory Animal Science Associations (FELASA) guidelines. Details regarding the
pathogen status of the NOG colony are reported in S3 Table. Procedures involving animals
were performed in accordance with the guidelines of the Catholic University of Leuven (KU
Leuven) Animal Care and Use Ethical Committee which specifically approved this study
(P147/2012).
Mouse Necropsy, histopathology and immunohistochemistry
Mice were euthanized by CO2 asphyxiation followed by complete pathological examination in-
cluding necropsy with dissection and histological analysis of the following organ and tissues:
head in toto, skin (including site of transplantation and auricles), salivary glands, larynx and
thyroids, trachea, lungs, heart, mediastinum, spleen, liver, pancreas, kidneys, esophagus and
stomach, small intestine, large intestine, urogenital tract, cervical and tracheobronchial lymph
nodes, sternum. Samples were immersion-fixed in 10% neutral buffered formalin (Sigma-Al-
drich #HT501320), routinely processed for paraffin embedding, sectioned at 5 μm and stained
with Hematoxylin (Diapath #C0302) and Eosin (Diapath #C0362). Serial sections obtained
from representative samples were also stained by means of immunohistochemistry (IHC) or in
situ hybridization (ISH) as detailed in the S2 Table. Head and sternum were decalcified in a
14% solution of Tetrasodium EDTA (VWR BDH Prolabo #20299291) for 15 days before pro-
cessing and paraffin embedding.
Mouse Hematology
Terminal blood collection was performed in 7 out of the 14 affected mice by means of cardiac
puncture. Complete blood count (CBC) was then measured using scil Vet ABC hematology an-
alyzer. Blood samples collected from 5 mice (i.e. 3 to 6 month-old non-transplanted and clini-
cally healthy NOG females housed in the same colony) were also included in the analysis
as controls.
IGH and IGK clonality assay
IgH and IgK rearrangements were studied by multiplex PCR with BIOMED-2 primers using a
BIOMED-2 PCR based protocol [22]. The final 50-μl reaction volume consists of 40-μl master-
mix, 1-2U of TaqGold (Applied Biosystems) and 100 ng of DNA for both IgH and IgK reac-
tions. The PCR reactions were performed on a ABI 9700 thermal cycler with the following
amplification parameters; initial denaturation for 15 minutes at 94°C, followed by 32 cycli of
30 seconds at 95°C, 30 seconds at 60°C and 30 seconds at 72°C, with a final extension step of
10 minutes at 72°C. PCR product was added into the appropriate well of a 96-well PCR plate.
A mix of HiDi Formamide and GeneScan-500 LIZ Size Standard was added into each well and
mixed with 2 μl PCR product and finally loaded to the ABI3130xl analyzer. Paraffin sections
from representative mouse lesions and matched frozen original tumor biopsies were used to
isolate genomic DNA. The quality of the extracted DNA was excellent, showing an amplifica-
tion up to 400 bp.
Results
Clinical history and necropsy findings in the affected NOGmice
Fourteen out of 116 (12%) F1 NOG females coming from 6/30 (20%) transplantation experi-
ments were submitted for complete necropsy and histopathology with a history of extensive
scaling/crusting dermatitis and alopecia (13/14) associated with progressive wasting/emacia-
tion (13/14) and poor/unsuccessful tumor engraftment (13/14) (Fig 1). Age of the affected F1
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Fig 1. Clinical and necropsy findings in the affected NOGmice xenotransplanted with tissues from humanmetastatic melanoma. (A) 5-month-old
female showing diffuse scaling and crusting dermatitis associated with alopecia. Note also the extreme emaciation of the animals and the complete absence
of grossly detectable tumor growth in the interscapular region. Scale bar = 15 mm. (B) Total white blood cell count assessment in 7 affected NOGmice and 5
healthy matched controls from the same NOG colony. Affected NOGmice display a significant increase in white blood cell counts when compared to healthy
controls (2-Tailed t-test, p = 0.012).
doi:10.1371/journal.pone.0124974.g001
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mice ranged between 2½ and 7 months. All the affected animals were transplanted with tissue
from patient-derived metastatic melanoma at 6 weeks of age. Additional gross findings re-
corded during necropsy included small whitish subcutaneous/fascial nodules at site of trans-
plantation (8/14), lymphadenomegaly mainly affecting cervical, tracheobronchial and renal
lymph nodes (12/14), enlargement of the thymus (4/14), mild to moderate splenomegaly (11/
14), mild hepatomegaly (6/14) and whitish mass in the cranial mediastinum (1/14) or renal
hilum (1/14). It must be recalled that, because of their severe hypoplasia, thymus and lymph
nodes in NOGmice are macroscopically inconspicuous. Hematological analysis performed on
7 of the affected animals also revealed a significant increase of white blood cell count when
compared to matched-control mice (Fig 1). An overview of the distribution of the affected F1
animals in the context of the different PDTX experiments is given in S1 Table.
Affected NOGmice suffer from a systemic immunoinflammatory disorder
with features of xenogeneic graft versus host disease
Microscopically, all the 14 affected animals exhibited infiltrates and/or proliferation of lym-
phoid cells in most of the analyzed organs and tissues with severe involvement of skin, salivary
glands, thyroids and lungs and prominent expansion of lymph nodes, thymus and spleen (Fig
2 and S1 Fig). Most of the lesions were composed of a variable mixture of small to medium-
sized lymphocytes and reactive plasma cells including numerous Mott cells. Skin lesions dis-
played a typical lichenoid interface pattern characterized by band-like infiltrates of lympho-
cytes and, to a lesser extent, plasma cells in the superficial-mid dermis with groups of small
epitheliotropic lymphocytes multifocally invading the hyperplastic/hyperkeratotic epidermis
and pilosebaceous units (Fig 2 and S1 Fig). Hydropic degeneration of the basal epidermal layer
and lymphocytic satellitosis with basal/suprabasal keratinocyte apoptosis were also evident. A
similar lesional pattern was also observed at the level of mucosal membranes lined by stratified
squamous epithelium (e.g. oral cavity, esophagus, forestomach, vagina) (S1 Fig). Other organs/
tissues showing different degrees of invasion and effacement of epithelial compartment by
groups of small lymphocytes included salivary glands, olfactory mucosa, respiratory mucosa,
thyroids, lungs (bronchioli), liver (bile ducts), pancreas (both exocrine and endocrine compart-
ments) and proximal gastrointestinal tract (S1 Fig). Lymphoid infiltrates were often associated
with variable degree of fibrosis. Most of the affected animals also displayed renal changes con-
sistent with membranous/membranoproliferative glomerulonephritis (S1 Fig).
Two main hypotheses were formulated that could explain the pathogenesis of these reactive
immunoinflammatory lesions: (i) development of immune cell “leakiness” in the mouse host
with spontaneous generation of functional B and T cell clones; (ii) establishment of a chronic
progressive form of human-into-mouse xenogeneic GVHD triggered by co-transplanted im-
mune cells populating the patient-derived biopsy. To test these two hypotheses, tissue sections
from representative lesions were immunostained with a monoclonal antibody that specifically
recognizes human but not mouse major histocompatibility complex (MHC) class I. Represen-
tative lesions were also stained with a monoclonal antibody that specifically recognizes murine
but not human CD45 Leukocyte Common Antigen (LCA). In addition, ISH for primate-specif-
ic Alu repetitive elements was performed to further test the human origin of the immune cells.
The entire population of lymphoid cells in the infiltrates displayed strong membranous MHC
class I immunoreactivity and diffuse positivity for Alu-ISH but invariably failed to express mu-
rine-specific CD45 LCA (Fig 2 and S2 Fig). These results unequivocally demonstrated the
human origin of the infiltrates thus supporting the hypothesis of the development of a chronic
GVHD-like condition initiated by human immune cells populating the original transplanted
biopsy. In order to provide further evidence of the causative relationship between lymphoid
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infiltrates of human origin and clinical condition affecting xenotransplanted NOGmice, histo-
logical examination and IHC for the human-specific MHC class I were also conducted on se-
lected tissue samples obtained from 9 clinically healthy NOGmice with successful metastatic
melanoma engraftment. As expected, infiltrates and/or proliferation of human lymphoid cells
were not detected in any of the examined organs and tissues including xenotransplanted
tumor, skin, salivary glands, lungs, lymph nodes, spleen, liver, pancreas, kidneys and urogenital
tract (S3 Fig).
Fig 2. Affected NOGmice xenotransplanted with tissue from humanmetastatic melanoma suffer from chronic xenogeneic GVHD-like condition
initiated by co-transplanted human immune cells populating the original tumor biopsy. (A-C) Chronic dermatitis with lichenoid interface pattern,
virtually all the infiltrating immune cells co-express the T cell marker CD3 and the human-specific MHC class I molecule HLA-A. Hematoxylin an eosin (HE)
staining and immunohistochemistry for CD3 and HLA-A, scale bar = 200 μm. (D-F) Dense plasma cell-rich infiltrates effacing the salivary gland parenchyma
and showing prominent nuclear expression of the mature B cells/plasma cells marker BLIMP1, virtually all the infiltrating immune cells are also positive for the
human-specific MHC class I molecule HLA-A. HE staining and immunohistochemistry for BLIMP1 and HLA-A, scale bar = 100 μm.
doi:10.1371/journal.pone.0124974.g002
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To characterize the nature of the lymphoid infiltrates responsible for the development of
the chronic GVHD-like condition, additional IHC stainings were performed. Not surprisingly,
epitheliotropic infiltrates in the skin and other organs/tissues were almost entirely composed of
CD3-positive T cells (Fig 2 and S4 Fig). On the contrary, plasma cell-rich infiltrates consisted
of a variable mixture of CD20/PAX5/BLIMP1-positive mature B cells, BLIMP1/CD138/
MUM1p-positive plasma cells and CD3-positive T cells (Fig 2). Co-localization studies using
the human-specific MHC class I monoclonal antibody were also performed to further confirm
the human origin of CD3-positive T cells and CD138-positive plasma cells populating the lym-
phoid infiltrates/proliferations (S4 Fig).
Melanoma xenografts in affected NOGmice are effaced by human
immune cells
In 8 out of 14 mice affected by xenogeneic GVHD-like condition, microscopic changes at site
of transplantation were characterized by dense plasma cell-rich lymphoid infiltrates of human
origin with severe effacement of melanoma xenografts as demonstrated by the identification of
scattered groups of Melan A, HMB45 and/or Tyrosinase-positive tumor cells interspersed
among the reactive infiltrates (Fig 3). As observed also in other organs/tissues, plasma cell-rich
infiltrates at site of transplantation were composed primarily of CD20/PAX5/BLIMP1-positive
mature B cells, BLIMP1/CD138/MUM1p-positive plasma cells and CD3-positive T cells (Fig
3). Similar tumor-effacing plasma cell-rich lymphoid infiltrates were not identified in any of
the original metastatic melanoma biopsies considered in this study.
Development of monoclonal post-transplant lymphoproliferative
disorders of donor origin in NOGmice suffering from xenogeneic GVHD-
like condition
In 2 out of the 14 animals affected by xenogeneic GVHD-like condition, we observed plasma
cell-rich lymphoid infiltrates with findings of marked cytologic atypia (i.e. anisocytosis, aniso-
karyosis, cytomegaly, karyomegaly, multinucleation and increased numbers of mitoses with ab-
errant mitotic figures) expanding the mediastinum and renal hilum, respectively (Fig 4). Also
in these cases, IHC for human-specific MHC class I and mouse-specific CD45 LCA confirmed
the human origin of the atypical infiltrates. Lesions were also immunostained for Melan A,
HMB45 and Tyrosinase but no positive cells were detected ruling out a possible combination
between atypical metastatic melanoma cells accompanied by dense plasma cell-rich lymphoid
infiltrates. On the contrary, atypical infiltrates were diffusely positive for markers of mature B
cell/plasma cell differentiation (i.e. CD20, PAX5, BLIMP1, CD138 and MUM1p) (Fig 4) and
showed kappa immunoglobulin light chain restriction suggesting a monoclonal expansion (Fig
5). In addition, plasma cells populating the atypical lesions showed an aberrantly high prolifer-
ative index as highlighted via duplex Ki67 and CD138 immunofluorescence (S5 Fig). The
monoclonal nature of these atypical mature B cell/plasma cell proliferations/infiltrates was fur-
ther demonstrated at molecular level (i.e. PCR for IGH and IGL loci rearrangement). Clonality
profiles from mouse lesions and matched original tumors are presented in Fig 5. In both the
atypical murine lymphoid infiltrates/proliferations, we observed a clear monoclonal pattern for
IGH and IGK. Representative tissue samples with plasma cell-rich lymphoid infiltrates, consid-
ered reactive based on microscopic examination, were also selected (as controls) from NOG
mice suffering from xenogeneic GVHD-like condition and confirmed to be polyclonal.
To rule out the possibility that lymphomatous cells were already coexisting with melanoma
metastases, the two original tumor biopsies (i.e. melanoma metastases from an inguinal and ax-
illary lymph node, respectively) were reviewed histopathologically, immunostained for
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immunoglobulin light chains and tested via PCR for IGH and IGK loci rearrangement. Micro-
scopically, no features of cytologic atypia were observed in the residual nodal structures or in
the scattered peritumoral infiltrates of lymphocytes and plasma cells. In both cases IHC failed
to demonstrate immunoglobulin light chain restriction and PCR confirmed the polyclonal na-
ture of B-cells and plasma cells populating the metastatic lesions.
Given the important role played by the Epstein-Barr Virus (EBV) and HHV-8 in the patho-
genesis of post-transplant lymphomagenesis, original patient biopsies and corresponding lym-
phomatous lesions in the mouse were also assessed via ISH and IHC for EBER1-2 and HHV-8,
respectively. All the samples tested negative for HHV-8 and original human metastases were
also negative for EBER1-2. On the contrary, one of the affected mice revealed a strong EBER1-
Fig 3. Metastatic melanoma xenografts in NOGmice affected by xenogeneic GVHD are effaced by plasma cell-rich lymphoid infiltrates. (A)
Xenotransplanted metastatic melanoma is replaced by dense lymphoid infiltrates diffusely expressing human-specific MHC class I molecule HLA-A. HLA-A
immunohistochemistry, scale bar = 100 μm. (B and C) Few residual groups of tyrosinase-positive melanoma cells are still detectable among the lymphoid
infiltrates. Tyrosinase immunohistochemical staining, scale bar = 200 μm in B and 50 μm in C. Lymphoid infiltrates at the site of transplantation are primarily
composed of MUM1p-positive plasma cells (D), CD20-positive mature B cells (E) and CD3-positive T cells. MUM1p, CD20 and CD3 immunohistochemistry,
scale bar = 100 μm.
doi:10.1371/journal.pone.0124974.g003
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2 signal involving approximately 30–40% of the atypical B cells/plasma cells populating the
monoclonal lymphomatous proliferation (Fig 5). Unfortunately there was no enough sample
material left to confirm/rule out the implication of EBV in the B cell malignancy from the
other affected mouse. Representative tissue samples with plasma cell-rich lymphoid infiltrates,
considered reactive based on microscopic examination, were also selected (as controls) from
NOGmice suffering from xenogeneic GVHD-like condition and confirmed to be negative for
both the viruses.
Taken together, these results confirm the development of post-transplant malignancies of
donor origin which are immunophenotypically consistent with diffuse large B cell lymphomas
with plasma cell differentiation. In one case it was also possible to demonstrate the implication
of EBV reactivation as the most likely cause of post-transplant B cell transformation.
Fig 4. NOGmice suffering from xenogeneic GVHD-like condition occasionally develop atypical plasma cell-rich lymphoid infiltrates of donor
origin. (A) Renal/perirenal plasma cell-rich infiltrates with findings of marked cytologic atypia. Hematoxylin and eosin staining (H&E), scale bar = 50 μm. (B)
Human origin of the atypical lymphoid infiltrates is confirmed through the diffuse expression of human-specific MHC class I molecule HLA-A. HLA-A
immunohistochemistry, scale bar = 100 μm. (C-F) Immunophenotypically the atypical lymphoid infiltrates are positive for markers of mature B cell/plasma cell
differentiation including CD20, BLIMP1, MUM1p, PAX5. CD20, BLIMP1, MUM1p and PAX5 immunohistochemistry, scale bar = 100 μm.
doi:10.1371/journal.pone.0124974.g004
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Fig 5. Atypical plasma cell-rich lymphoid infiltrates of donor origin in NOGmice xenotransplanted with humanmetastatic melanoma are
monoclonal and reflect the development of post-transplant B cell/plasma cell malignancies associated with Epstein-Barr virus (EBV) reactivation.
(A) The atypical plasma cell-rich infiltrates show kappa light chain restriction suggesting monoclonal B cell/plasma cell expansion. Kappa and Lambda light
immunoglobulin chains immunohistochemistry, scale bar = 100 μm. (B) Atypical lymphoid infiltrates show a clear monoclonal pattern for all IgH and IgK
frameworks confirming the development of post-transplant B cell/plasma cell neoplasms, fragment lenght for each monoclonal peak is indicated (left). On the
contrary, matched original human tumor biopsy displays a polyclonal pattern which is consistent with the presence of reactive B cells/plasma cells (right).
Multiplex PCR for IgH and IgK rearrangements. (C) Approximately 30–40% of the atypical B cells/plasma cells populating the monoclonal lymphoid
proliferation display a strong EBV-encoded RNA (EBER1-2) hybridization signal (left). On the contrary no EBER1-2 signal is observed in the original tumor
biopsy (right) suggesting a post-transplant reactivation of EBV. EBER1-2 in situ hybridization, scale bar = 100 μm.
doi:10.1371/journal.pone.0124974.g005
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Discussion
A revolutionary aspect of NSG and NOGmice is the ability to promote efficient engraftment
and expansion of diverse repertoires of leukocytes from different animal species including hu-
mans [11,23]. Thanks to this unique feature, both mouse lines are currently widely exploited in
the preclinical field to generate mouse models with humanized immune system for studying
immunopathological conditions [e.g. GVHD, delayed-type hypersensitivity (DTH)] [24,25],
viral infections primarily targeting immune cells [e.g. human immunodeficiency virus (HIV)
and EBV infections] [26]) and immunotherapeutic strategies (e.g. vaccine discovery and cancer
immunotherapy) [27,28]. Although advantageous in diverse experimental settings, here we
demonstrate that this capability of NOG mice to allow the engraftment of functional human
immune cells may have unpredictable repercussion on the development of PDTX models. Co-
transplanted lymphoid cells have indeed the potential to colonize systemically the recipient
mouse, expand in vivo and eventually promote (i) immunoinflammatory disorders with fea-
tures of xenogeneic GVHD, (ii) effacement of xenografted tumor at site of transplantation and
(iii) monoclonal PTLD in the form of B cell lymphomas.
As it can be inferred from the complete overview of the different PDTX experiments includ-
ed in our melanoma platform, clear correlations could not be found between the main clinico-
pathological characteristics of the original tumor (e.g. location of the metastasis, nature of the
transplanted material in terms of tumor content and presence of lymphoid components, etc.)
and the development of the post-transplant disorders described in the present study. The oc-
currence of the different post-transplant entities in mice receiving the same biopsy material
was also unpredictable and not consistently reproducible. This is demonstrated by the fact that,
within the same F1 transplant group, some animals only developed xenogeneic GVHD, some
showed xenogeneic GVHD in combination with one or both of the other post-transplant disor-
ders and some displayed a successful tumor engraftment without any clinical abnormality.
The development of xenogeneic GVHD has been already described as a major limitation in
NSG mice receiving mononuclear cells from patients with acute myeloid leukemia (AML)
without T cell depletion before transplantation [29]. In this experimental setting, NSG model
proved to be unsuitable for preclinical applications as the high frequency of xenogeneic GVHD
was consistently associated with failure of leukemic cell engraftment and premature mouse
death. Similarly, we observed that more than 10% of NOGmice transplanted with biopsy mate-
rial from metastatic melanoma exhibited unsuccessful tumor engraftment associated with dif-
fuse dermatitis and progressive deterioration of health status ultimately requiring premature
euthanasia. The comprehensive clinicopathological characterization of this entity revealed ex-
tensive immunoinflammatory changes in organs and tissues that are characteristically impli-
cated during chronic GVHD (e.g. skin and adnexa, mucous membranes, salivary glands and
portal spaces) [30]. In addition, the distinct patterns of lesion distribution (i.e. T cell infiltrates
with lichenoid interface pattern in the skin and mucous membranes), coupled with the demon-
stration of the human origin of infiltrating lymphoid cells, provided unequivocal evidence for
the development of human-into-mouse xenogeneic GVHD triggered by immune cells populat-
ing the transplanted tumor samples. Importantly, confirmation of the human origin of lym-
phoid cells definitely ruled out the possibility that these lesions may have resulted from
spontaneous generation of mouse T and B cell (phenomenon also referred to as “leakiness”).
Leakiness, which is a well-documented (usually age-related) limiting factor for tumor engraft-
ment in immunocompromised mouse lines carrying the Prkdcscid mutation, is indeed reported
as an exceedingly rare or nonexistent event in NOG or NSG mice [12,31,32].
It is currently unclear whether a correlation exists between the development of human-into-
mouse xenogeneic GVHD and the nature of the transplanted tumor and/or tumor-associated
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lymphocyte repertoires. Melanoma is actually considered one of the most highly immunogenic
tumors capable of inducing a strong immune response against a vast array of tumor-associated
antigens [33]. In this context, it is interesting to note that xenogeneic GVHD also emerged as a
major limiting factor in NSG mice bearing xenografts from established melanoma cell lines
and receiving adoptive cell therapy with the melanoma-associated antigen MART-1-specific
human T cells [28]. These observations, together with the findings described in our study, sug-
gests that beside the classical xeno-immune response against foreign major and minor histo-
compatibility complexes [34], molecular mimicry between dominant melanoma-associated
antigens and undetermined mouse epitopes may also play a role in the development of xenoge-
neic GVHD. Further supporting this view, significant expansion of co-transplanted lymphoid
cells but lack of xenogeneic GVHD have been recently reported in NSG mice xenotransplanted
with patient-derived non-small cell lung cancer which is notoriously regarded as poorly immu-
nogenic tumor [15,33]. Another aspect that would definitely be very interesting to assess in a
prospective study is whether the risk for xenogeneic GVHD is contributed by specific determi-
nants present in the MHC haplotype of the donor [35].
In the clinical setting, melanoma invasion by plasma cells is an exceedingly rare finding that
is occasionally described in primary cutaneous melanoma [36]. The same has been confirmed
also in this study where none of the original metastatic melanoma biopsies exhibited this feature.
Conversely, we observed that the majority of transplanted animals suffering from GVHD-like
condition displayed unsuccessful melanoma engraftment associated with severe effacement of
tumor xenografts by dense infiltrates of donor B-cells, plasma cells and T-cells. Although the
exact pathogenesis of this finding remains largely unclear, possible speculations can be made to
explain the extensive replacement of melanoma xenografts by co-transplanted immune cells.
Considering the well-documented resistance of metastatic melanoma to antibody-mediated kill-
ing mechanisms [i.e. complement-dependent cytotoxicity (CDC), antibody-dependent cellular
cytotoxicity (ADCC)] [37–39], development of an effective adaptive humoral immune attack
against malignant cells after tumor transplantation into NOG recipients emerges as the most at-
tractive scenario. This hypothesis actually opens interesting perspectives on whether, under the
influence of a highly permissive recipient microenvironment [27], specific subsets of co-trans-
planted immune cells (which are normally repressed/quiescent in the original metastatic lesions)
could have been selected to mount an effective humoral immunity circumventing melanoma im-
mune escape strategies. In addition, xenotransplantation event might have played a role in the
activation of a robust immune response against melanoma cells by unmasking novel dominant
antigens that were concealed/segregated from the immune system in the original metastatic le-
sions. Although PDTXs in NSG and/or NOGmice are considered relatively stable models re-
flecting biologically the original tumor in the patient [4,5,8], profound variation in the spectrum
of tumor-associated antigens represents indeed a well-described phenomenon which is frequent-
ly encountered in the context of xenotransplantation experiments [40–43]. Although in our
study a humoral immune response appears to be the main mechanism responsible for the efface-
ment of patient-derived melanoma xenografts, the heterogeneous population of T and B cells
frequently observed at site of transplantation suggests that additional immune strategies may
have also played a role. In this context, a recent investigation demonstrates that synergic interac-
tions between 4-1BBL-expressing B cells and CD8-positive cytotoxic T cells can significantly
contribute to reduce melanoma growth in syngeneic mouse models [44].
The development of a monoclonal PTLD of donor origin in 2 of the 14 NOGmice suffering
from xenogeneic GVHD-like disease was another unanticipated finding. In both cases, immuno-
histological and molecular characterization of the atypical lymphoproliferative lesion confirmed
the development of a mature B cell malignancy (most likely a DLBCL) with features of plasma
cell differentiation [45]. EBV reactivation is responsible for B cell transformation in most of the
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reported clinical cases of post-transplant B cell lymphomas of donor origin [46–48]. Similarly, we
were able to demonstrate reactivation of EBV infection as the most likely event driving post-
transplant B cell lymphoma development in one of the two affected NOGmice. Strong EBER1-2
signal was indeed revealed in the atypical B cells/plasma cells populating the monoclonal lympho-
matous proliferation whereas original tumor biopsy and reactive lymphoid infiltrates observed at
site of transplantation or in the context of human-into-NOGmouse xenogeneic GVHD-like con-
dition tested negative. Reactivation of EBV infection in co-transplanted human lymphocytes was
also recently documented in a series of NOG or NSG-based PDTX experiments including breast,
colorectal, gastric, lung and prostate [49,50]. In these latter works, EBV was identified by means
of IHC and/or ISH in the context of lymphoproliferative lesions of B cell origin at the site of trans-
plantation. Despite some aspects concerning the pathobiology of the lymphoproliferative lesions
reported in these studies have not been fully elucidated (e.g. reactive versus neoplastic nature of
the lymphoid proliferations, differentiation between co-transplanted human and native murine
immune cells, evidence of lymphomatous proliferations in the original tumor biopsies and status
of EBV infection in the human patients), similarities between our findings and their observations
corroborate the general view that EBVmay drive PTLD of donor origin in diverse NOG or NSG
mouse-based PDTX experimental contexts [49–51].
In conclusion, the possibility for the development of xenogeneic GVHD driven by human
immune cells populating the original tumor samples should be considered as a possible limita-
tion in the context of NOG model-based PDTX experiments as this entity primarily impacts
on the rate of tumor engraftment/growth and animal lifespan. The condition may also repre-
sent a major confounding factor for efficacy studies and personalized therapy trials where im-
paired tumor engraftment/growth can be potentially misinterpreted as positive response to
treatment [7]. On the other hand, the replacement of the melanoma at the site of transplanta-
tion by a dense infiltrate of T-cells and plasma cells also marks an ongoing immune response
against the tumor, resulting in a loss of melanoma cells, and thus may aid in the identification
of novel tumor-antigens and establishment of effective immunotherapies. Lastly, the detailed
characterization of B cell neoplasms of donor origin in our experimental setting reinforces the
notion that NOGmice transplanted with patient-derived tumors may have a specific proclivity
for the development of PTLD following the reactivation of EBV infection in the recipient host.
Supporting Information
S1 Fig. Histopathology of the immunoinflammatory lesions affecting NOGmice xeno-
transplanted with tissues from human metastatic melanoma. Dense infiltrates/proliferations
of reactive lymphocytes and/or plasma cells with: (A) expansion of the fibrotic auricular dermis
and epitheliotropic invasion of the hyperplastic/hyperkeratotic epidermis and pilosebaceous
units, (B) expansion of cervical lymph node and invasion/effacement of the adjacent fibrotic pa-
rotid gland, (C) almost complete effacement of thyroid gland, (D) diffuse infiltration of pulmo-
nary parenchyma, (E) multifocal infiltration of the renal cortex associated with membranous
glomerulonephritis, (F) epitheliotropic invasion of the oral mucosa, (G) expansion of white
pulp in the spleen [(H) note the undistinguishable hypoplastic white pulp in a non-affected
NOGmice]. H&E staining. Scale bar = 100 μm (A, E, F), 200 μm (B, C) and 400 μm (D, G, H).
(TIF)
S2 Fig. Demonstration via immunohistochemistry and in situ hybridization of the human
origin of lymphoid infiltrates in the NOGmice affected by xenogeneic GVHD-like condi-
tion. (A and B) The great majority of immune cells in the perivascular pulmonary infiltrates
are positive for primate-specific Alu repeats and human-specific MHC class I molecule
HLA-A. (C) On the contrary, only scattered cells (most likely resident macrophages and
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dendritic cells) are labeled by the mouse specific CD45/LCA antibody. HLA-A and CD45/LCA
immunohistochemistry and Alu repeats in situ hybridization, scale bar = 100 μm.
(TIF)
S3 Fig. Demonstration via immunohistochemistry that lymphoid infiltrates of human ori-
gin are not present in tissues and organs obtained from clinically healthy NOGmice with
successful metastatic melanoma engraftment. (A) Immune cells expressing the human-spe-
cific MHC class I molecule HLA-A are not evident in the salivary glands. (B) Metastatic mela-
noma xenograft with overlying skin, note that the xenotransplanted tumor diffusely expresses
the human-specific MHC class I molecule HLA-A but no positive infiltrates of immune cells
are detectable in the overlying skin or peritumoral soft tissues. HLA-A immunohistochemistry,
scale bar = 200 μm.
(TIF)
S4 Fig. Co-localization studies confirm the human origin of T lymphocytes and plasma
cells in the lymphoid infiltrates affecting NOGmice xenotransplanted with tissues from
human metastatic melanoma. Virtually all the infiltrating CD138-positive plasma cells and/or
CD3-positive T cells also express the human-specific MHC class I molecule HLA-A. (A)
Human plasma cells expanding the cervical lymph node of an affected NOGmouse. Duplex
HLA-A and CD138 immunofluorescence, scale bar = 35 μm. (B) Epitheliotropic infiltrates of
human T cells in the salivary gland of an affected NOGmouse. Duplex HLA-A and CD3 immu-
nofluorescence, scale bar = 75 μm. (C) Prominent expansion of human T cells in the thymus of
an affected NOGmouse. Duplex HLA-A and CD3 immunofluorescence, scale bar = 100 μm.
(TIF)
S5 Fig. Atypical plasma cell-rich lymphoid infiltrates of donor origin in NOGmice xeno-
transplanted with metastatic human melanoma are characterized by exceptionally high
proliferative activity. (A) CD138-positive plasma cells populating the atypical lymphoid infil-
trates display an aberrantly high proliferative index. (B) Note the absence of Ki67-positive plas-
ma cells in hepatic lesions characterized by non-atypical lymphoid infiltrates which were
considered reactive based on microscopic examination. Duplex Ki67 and CD138 immunofluo-
rescence, scale bar = 50 μm.
(TIF)
S1 Table. Complete overview of the different PDTX experiments included in the melanoma
platform. The table delineates distribution and frequency of the different of post-transplant disor-
ders developed by xenotraspanted NOGmice how they correlate with the original tumor biopsies.
(XLSX)
S2 Table. Details concerning reagents and procedures used for immunohistochemistry and
in situ hybridization.
(DOCX)
S3 Table. Health report with the pathogen status of the NOG colony.
(DOCX)
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